RU2370495C2 - Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора - Google Patents
Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора Download PDFInfo
- Publication number
- RU2370495C2 RU2370495C2 RU2006128446/04A RU2006128446A RU2370495C2 RU 2370495 C2 RU2370495 C2 RU 2370495C2 RU 2006128446/04 A RU2006128446/04 A RU 2006128446/04A RU 2006128446 A RU2006128446 A RU 2006128446A RU 2370495 C2 RU2370495 C2 RU 2370495C2
- Authority
- RU
- Russia
- Prior art keywords
- applicaition
- antagonists
- heterocyclic compounds
- glutamate receptor
- metabotropic glutamate
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims abstract 4
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 3
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60896004P | 2004-02-18 | 2004-02-18 | |
| US60/608,960 | 2004-02-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006128446A RU2006128446A (ru) | 2008-03-27 |
| RU2370495C2 true RU2370495C2 (ru) | 2009-10-20 |
Family
ID=35447957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006128446/04A RU2370495C2 (ru) | 2004-02-18 | 2005-02-15 | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US7585881B2 (https=) |
| EP (2) | EP2311830A1 (https=) |
| JP (1) | JP4912157B2 (https=) |
| CN (2) | CN1984907A (https=) |
| AT (1) | ATE483706T1 (https=) |
| AU (1) | AU2005270208A1 (https=) |
| BR (1) | BRPI0507497A (https=) |
| CA (1) | CA2555566A1 (https=) |
| CY (1) | CY1110965T1 (https=) |
| DE (1) | DE602005023963D1 (https=) |
| DK (1) | DK1723144T3 (https=) |
| ES (1) | ES2352110T3 (https=) |
| HR (1) | HRP20100654T1 (https=) |
| IL (1) | IL177394A0 (https=) |
| NO (1) | NO20063599L (https=) |
| NZ (1) | NZ548954A (https=) |
| PL (1) | PL1723144T3 (https=) |
| PT (1) | PT1723144E (https=) |
| RS (1) | RS51516B (https=) |
| RU (1) | RU2370495C2 (https=) |
| SG (1) | SG146657A1 (https=) |
| SI (1) | SI1723144T1 (https=) |
| UA (1) | UA84318C2 (https=) |
| UY (1) | UY28766A1 (https=) |
| WO (1) | WO2006014185A1 (https=) |
| ZA (1) | ZA200606551B (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014881A2 (en) * | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| JP2007533743A (ja) * | 2004-04-20 | 2007-11-22 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病治療のためのβ−セクレターゼ阻害薬として有用な１，３，５−置換フェニル誘導体化合物 |
| JPWO2006080533A1 (ja) * | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | ３−アミノ−１，２，４−トリアゾール誘導体 |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
| TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
| CA2657247A1 (en) * | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
| EP2167464B1 (en) * | 2007-05-25 | 2014-12-03 | AbbVie Deutschland GmbH & Co KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
| JP2010533147A (ja) | 2007-07-13 | 2010-10-21 | アデックス ファルマ エス．エイ． | 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体 |
| BRPI0818448A2 (pt) * | 2007-10-19 | 2015-05-12 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5. |
| WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
| WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
| CA2704684A1 (en) * | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| CA2718166A1 (en) * | 2008-03-03 | 2009-09-17 | Stiefel Laboratories, Inc. | Processes for preparing enantiomerically pure diol and dioxolane compounds |
| EP3782991A1 (en) | 2008-05-14 | 2021-02-24 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| US8178568B2 (en) * | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
| WO2010019100A1 (en) * | 2008-08-12 | 2010-02-18 | Astrazeneca Ab | A new crystalline form of 4- (5- { (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4h-l, 2, 4- triazol-3-yl) pyridine |
| EP2324019A4 (en) * | 2008-08-12 | 2011-10-05 | Astrazeneca Ab | CRYSTALLINE FORM OF (5- {(IR) -1- [5- (3-CHLOROPHENYL) ISOXAZOL-3-YL] ETHOXY} -4-METHYL-4H-L, 2, 4-TRIAZOL-3-YL) -PYRIDINE |
| CA2737639A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| EP2379531A1 (en) * | 2008-12-18 | 2011-10-26 | AstraZeneca AB | Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy]-4h- [1,2, 4]triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl]ethanol |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| JP5705748B2 (ja) | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を変調する複素環化合物 |
| WO2010114971A1 (en) * | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
| CA2764339A1 (en) * | 2009-06-05 | 2010-12-09 | Oslo University Hospital Hf | Azole derivatives as wtn pathway inhibitors |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| WO2011037795A1 (en) * | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| MX2012005560A (es) * | 2009-11-13 | 2012-10-05 | Receptos Inc | Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral. |
| PH12012500940B1 (en) * | 2009-11-13 | 2018-09-26 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| ES2665461T3 (es) * | 2009-11-13 | 2018-04-25 | Celgene International Ii Sàrl | Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral |
| CN101712641B (zh) * | 2009-12-29 | 2013-05-08 | 江苏工业学院 | 一种甲硫基苯甲酸的制备方法 |
| ES2443578T3 (es) * | 2009-12-29 | 2014-02-19 | Eli Lilly And Company | Compuestos de tetrahidrotriazolopiridina como potenciadores de receptores selectivos de mGlu5 útiles para el tratamiento de la esquizofrenia |
| WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
| EP2632900A2 (en) * | 2010-10-28 | 2013-09-04 | Merck Sharp & Dohme Corp. | Caprolactam mglur5 receptor modulators |
| RU2013128448A (ru) | 2010-12-08 | 2015-01-20 | Осло Юниверсити Хоспитал Хф | Производные триазола в качестве ингибиторов сигнального пути wnt |
| DE102010063974B4 (de) * | 2010-12-22 | 2021-10-07 | Thomas Rühl | Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung |
| AU2012232711B2 (en) | 2011-03-18 | 2016-04-28 | Novartis Ag | Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease |
| US8759380B2 (en) * | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
| JP6858129B2 (ja) * | 2015-03-05 | 2021-04-14 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 置換されたフェニルイソオキサゾリン誘導体の製造方法 |
| KR102894264B1 (ko) | 2015-03-10 | 2025-12-02 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| BR112017019304A2 (pt) * | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| EP3694841A1 (en) | 2017-10-11 | 2020-08-19 | Aurigene Discovery Technologies Limited | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| MY206121A (en) | 2017-11-03 | 2024-11-29 | Aurigene Discovery Tech Ltd | Dual inhibitors of tim-3 and pd-1 pathways |
| AU2018360389B2 (en) | 2017-11-06 | 2024-09-19 | Aurigene Oncology Limited | Conjoint therapies for immunomodulation |
| US11103468B2 (en) | 2017-11-16 | 2021-08-31 | Montdorex Inc. | Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| PT3911647T (pt) | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| CA3139063A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| KR20220097405A (ko) * | 2019-11-05 | 2022-07-07 | 클라에스 툴린 | 포유동물에서의 혹사의 예방 및/또는 치료에 사용하기 위한 4-[5-[(rac)-1-[5-(3-클로로페닐)-3-이속사졸일]에톡시]-4-메틸-4H-1,2,4-트리아졸-3-일]피리딘 |
| WO2021142006A1 (en) * | 2020-01-07 | 2021-07-15 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CA3169779A1 (en) | 2020-02-28 | 2021-09-02 | Andrew Mark Griffin | Kcnt1 inhibitors and methods of use |
| TWI904906B (zh) | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| WO2022231872A1 (en) * | 2021-04-29 | 2022-11-03 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| PL4514782T3 (pl) | 2022-05-19 | 2026-02-23 | Astrazeneca Ab | Związki amidoheteroaromatyczne przydatne w leczeniu chorób wątroby |
| WO2025212948A1 (en) * | 2024-04-04 | 2025-10-09 | University Of Iowa Research Foundation | Therapeutic compounds and methods |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2218340C2 (ru) * | 1998-03-11 | 2003-12-10 | Ф.Хоффманн-Ля Рош Аг | ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ И ПИРАЗОЛО[1,5-а]ТРИАЗИНЫ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4538833A (en) * | 1983-12-08 | 1985-09-03 | P I E International Inc. | Publication |
| US5403138A (en) * | 1991-10-09 | 1995-04-04 | Fuji Photo Film Co., Ltd. | Booklet album including a double-sided photograph and a method of making the same |
| US5332265A (en) * | 1993-01-22 | 1994-07-26 | Minnesota Mining And Manufacturing Company | Advertising assembly |
| KR100875222B1 (ko) | 1999-08-19 | 2008-12-19 | 아스트라제네카 아베 | 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도 |
| WO2003053922A2 (en) | 2001-12-19 | 2003-07-03 | Merck & Co., Inc. | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| US7074809B2 (en) * | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
| TW200424183A (en) | 2002-08-09 | 2004-11-16 | Nps Pharma Inc | New compounds |
| WO2004014881A2 (en) * | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
-
2005
- 2005-02-09 US US11/053,752 patent/US7585881B2/en not_active Expired - Fee Related
- 2005-02-15 EP EP10182161A patent/EP2311830A1/en not_active Withdrawn
- 2005-02-15 CA CA002555566A patent/CA2555566A1/en not_active Abandoned
- 2005-02-15 AT AT05802855T patent/ATE483706T1/de active
- 2005-02-15 SI SI200531175T patent/SI1723144T1/sl unknown
- 2005-02-15 EP EP05802855A patent/EP1723144B1/en not_active Expired - Lifetime
- 2005-02-15 AU AU2005270208A patent/AU2005270208A1/en not_active Abandoned
- 2005-02-15 PL PL05802855T patent/PL1723144T3/pl unknown
- 2005-02-15 NZ NZ548954A patent/NZ548954A/xx unknown
- 2005-02-15 BR BRPI0507497-5A patent/BRPI0507497A/pt not_active IP Right Cessation
- 2005-02-15 RS RSP-2010/0525A patent/RS51516B/sr unknown
- 2005-02-15 RU RU2006128446/04A patent/RU2370495C2/ru not_active IP Right Cessation
- 2005-02-15 DK DK05802855.6T patent/DK1723144T3/da active
- 2005-02-15 CN CNA2005800043063A patent/CN1984907A/zh active Pending
- 2005-02-15 PT PT05802855T patent/PT1723144E/pt unknown
- 2005-02-15 JP JP2006554165A patent/JP4912157B2/ja not_active Expired - Fee Related
- 2005-02-15 WO PCT/US2005/004774 patent/WO2006014185A1/en not_active Ceased
- 2005-02-15 CN CNA2007101278476A patent/CN101096368A/zh active Pending
- 2005-02-15 US US10/588,702 patent/US20070179188A1/en not_active Abandoned
- 2005-02-15 SG SG200806914-8A patent/SG146657A1/en unknown
- 2005-02-15 DE DE602005023963T patent/DE602005023963D1/de not_active Expired - Lifetime
- 2005-02-15 HR HR20100654T patent/HRP20100654T1/hr unknown
- 2005-02-15 ES ES05802855T patent/ES2352110T3/es not_active Expired - Lifetime
- 2005-02-15 UA UAA200608867A patent/UA84318C2/ru unknown
- 2005-02-18 UY UY28766A patent/UY28766A1/es not_active Application Discontinuation
-
2006
- 2006-08-07 ZA ZA200606551A patent/ZA200606551B/en unknown
- 2006-08-08 NO NO20063599A patent/NO20063599L/no not_active Application Discontinuation
- 2006-08-09 IL IL177394A patent/IL177394A0/en unknown
-
2007
- 2007-08-18 US US11/840,954 patent/US20070293545A1/en not_active Abandoned
- 2007-08-18 US US11/840,953 patent/US20080045571A1/en not_active Abandoned
- 2007-08-18 US US11/840,952 patent/US20080015234A1/en not_active Abandoned
- 2007-08-18 US US11/840,955 patent/US20080015204A1/en not_active Abandoned
-
2010
- 2010-12-03 CY CY20101101116T patent/CY1110965T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2218340C2 (ru) * | 1998-03-11 | 2003-12-10 | Ф.Хоффманн-Ля Рош Аг | ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ И ПИРАЗОЛО[1,5-а]ТРИАЗИНЫ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2370495C2 (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
| RU2401658C2 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| EA200501075A1 (ru) | Лекарственное средство для профилактики и лечения артериосклероза и гипертензии | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
| IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
| TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| ATE370948T1 (de) | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen | |
| EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
| EP2178870A4 (en) | INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS | |
| SE0401971D0 (sv) | Piperidne derivatives | |
| EA200300354A1 (ru) | Хинолиноновые производные в качестве ингибиторов тирозинкиназы | |
| TW200621249A (en) | Substituted amide beta secretase inhibitors | |
| ATE413388T1 (de) | Muskarin antagonisten | |
| EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
| EA200400467A1 (ru) | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора | |
| EA200700027A1 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
| DE60313350D1 (de) | Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 29-2009 FOR TAG: (73) |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120216 |